Damora Therapeutics (DMRA) logo

Damora Therapeutics (DMRA) stock

Hematologic biologics , market cap $1.5B

$23.22
-4.44%

Quality Score
-1
Poor
In its industry
#110of 273
Checks firing
2of 14
Transition
From its high
-33.4%
under its best since listing

DMRA's Quality Score fell 3 points on Fri, Nov 20, to -1. Buying slipped from its highest in 20 days (3 chart checks stopped).

New listing, trading since Mar 10, 2026. 179 trading days so far, so 1 of the 14 chart checks waits for more history.

Follow DMRA's trial news. Pro members can get an alert when Damora Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when DMRA files news on its trialSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$528M in cash. One of the last four quarters brought cash in while the others used it.On Sep 30 · the company says “into 2029”

Key facts on DMRA

Key facts on DMRA
Holding it backA $292M loss wider than $16M a year earlier
Latest filing10-Q, Nov 4 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

What's next

Mon Nov 30: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Cash$528M in cash. One of the last four quarters brought cash in while the others used it.On Sep 30 · the company says “into 2029”

DMRA catalysts

Coming up

After its last report it closed -4.7%.

What's next for DMRA, and how long its cash lasts

Its trials

A trial underway
CLARITY-101Phase 1 · Recruiting · 250 people · main data estimated Jun 2030 · NCT07849231

For Pro members: 21 filings.

Cash runway Sep 30 balance sheet

$528M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2029” (8-K, Jan 12).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Feb 10, 2026)
  • At-the-market share sales program (S-3ASR, filed Feb 10, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CEO Jennifer Jarrett bought 12,500 shares on Sep 25. 4 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Jennifer Jarrett’s 4 filings and quotes.

Get an alert when DMRA files news on its trialA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why DMRA scores -1

Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

  • +2Chart checks 2 of 14 firing right now, one point each
  • −1Profit A loss of $292M over the last four quarters, more than the $16M lost a year earlier, from the SEC filingsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Long-term trend, Run-up, Size, Growth, Dilution, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on DMRA and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when DMRA's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How DMRA ranks in Biotech

DMRA is #110 of 273 by Quality Score.

How DMRA ranks in Biotech
RankStockQuality Score
110Damora Therapeutics (DMRA) logoDMRADamora Therapeutics-1

More in Biotech

When does DMRA report earnings, and what happens after?

Expected to report Thu Mar 18, after the close (in 117 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 1

-4.7%
Nov 4
ReportedGapReaction5
days
Nov 4, 2026After close+0.9%-4.7%+1.4%

DMRA closed higher after 0 of its last 1 report.

DMRA has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on DMRA, and all 14 on every stock.Get in free →See the top 3 →Start Pro

DMRA RSI on Nov 20: 54.1, above its 50-day average

Not scored

RSI 54.1, MACD above signal. Not scored.

6 more findings on DMRA, each with its source, for Pro members.

DMRA share count over time

Shares: 46.6 times the count a year ago (to Sep 30).

Shares of DMRA outstanding, as filed
Shares
outstanding
As
of
61.9MNov 2, 2026
61.7MAug 7, 2026
61.6MMay 11, 2026
60.3MMar 17, 2026
Offerings, shelves, and splits of DMRA, from its filings
From its
filings
Filed
Raised $275M in a sale of shares, about 18% of its market valueFeb 11, 2026
Registered shares for a later sale (S-3ASR)Feb 10, 2026
Registered shares for a later sale (S-3)Dec 16, 2025

DMRA insider trades

One insider bought $253K across 1 filing, and one insider sold $7K across 1 filing, in the last 6 months. The newest:

BuyJennifer Jarrett$253KDirector, President and CEOat $20.23 on Sep 25, filed Sep 28

DMRA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

About Damora Therapeutics

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

7 employeesWaltham, MAdamoratx.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on DMRA and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn DMRA's score around: 6 things
  • 3 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawaySep 28Jennifer Jarrett bought DMRA$253K at $20.23, filed Sep 28

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: DMRA's Quality Score is -1 (Poor), #110 of 273 in Biotech. Insiders bought $253K and sold $7K in the last 6 months (Form 4).

What does DMRA's Quality Score say?

DMRA scores -1 today, which Breakaway calls Poor. It is #110 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Shares: 46.6 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is DMRA's Quality Score?

DMRA scores -1 today, which Breakaway calls Poor (below zero). That is #110 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DMRA's -1.

Are insiders buying DMRA?

One insider bought $253K across 1 filing, and one insider sold $7K across 1 filing, in the last 6 months. The newest is Jennifer Jarrett, Director, President and CEO, who bought $253K on Sep 25. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Damora Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.